Literature DB >> 7014226

Intensive combination chemotherapy with vincristine, adriamycin and prednisolone (VAP) in the treatment of diffuse histology non-Hodgkin's lymphoma. (A report of 89 cases with extensive disease from the Manchester Lymphoma Group).

G Blackledge, H Bush, J Chang, D Crowther, D P Deakin, O G Dodge, J V Garrett, M Palmer, D Pearson, J H Scarffe, I D Todd, P M Wilkinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7014226     DOI： 10.1016/0014-2964(80)90056-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  7 in total

1.  A pilot study of cyclical chemotherapy with high-dose methotrexate and CHOP (MTX-CHOP) in poor-prognosis non-Hodgkin's lymphoma (NHL).

Authors:  J A Child; D L Barnard; S C Cartwright; I Lauder; A V Simmons; J Stone; J Thorogood
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

2.  A new approach to the treatment of advanced high-grade non-Hodgkin's lymphoma--intensive two-phase chemotherapy.

Authors:  N S Stuart; G R Blackledge; J A Child; J Fletcher; T J Perren; C J O'Brien; E L Jones; I O Ellis; J A Kavanagh; K A Kelly
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer.

Authors:  H Anderson; P Hopwood; J Prendiville; J A Radford; N Thatcher; L Ashcroft
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

4.  Workshop on large-cell lymphomas. 6 June 1981, Newcastle, England. Extended abstracts.

Authors: 
Journal:  Br J Cancer       Date:  1981-12       Impact factor: 7.640

5.  New approaches to the management of patients with non-Hodgkin's lymphoma of high-grade pathology. First Gordon Hamilton-Fairley memorial lecture.

Authors:  D Crowther
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

6.  Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.

Authors:  R A Cowan; M Jones; M Harris; W P Steward; J A Radford; J Wagstaff; D P Deakin; D Crowther
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

7.  Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial.

Authors:  H Anderson; J H Scarffe; R N Sutton; E Hickmott; D Brigden; C Burke
Journal:  Br J Cancer       Date:  1984-07       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.